Alpha-endorphin, gamma-endorphin and their des-tyrosine fragments in rat pituitary and brain tissue

Quantification of endogenous alpha- and gamma-endorphins in rat brain by liquid chromatography-tandem mass spectrometry

Quantification of alpha- and gamma-endorphins in rat brain using liquid chromatography-electrospray ionization-tandem mass spectrometry is described. [D-Ala(2)]-gamma-endorphin is used as an internal standard. The precursor-to-product ion MRM transitions for alpha-endorphin, gamma-endorphin, and [D-Ala(2)]-gamma-endorphin were m/z 873.6-->429.6; 929.6-->542.3; 936.6-->542.3, respectively. The method was validated in terms of linearity, specificity, sensitivity, recovery, precision, and accuracy. The assay was linear over a concentration range of 0.1-200 ng/mL with the limit-of-detection of 0.03 ng/mL and limit-of-quantification of 0.1 ng/mL. The endogenous concentrations of alpha- and gamma-endorphins in rat brains were 13.8+/-0.57 (mean+/-SD; n=5) and 2.5+/-0.43 ng/g of wet tissue weight, respectively.

Effects of mediobasal hypothalamic lesion on immunoreactive ACTH/beta-endorphin levels in cerebrospinal fluid, in discrete brain regions, in plasma, and in pituitary of the rat

One week after complete destruction of the mediobasal hypothalamus, immunoreactive adrenocorticotropin (ACTH) and beta-endorphin levels were determined in cerebrospinal fluid, trunk blood, as well as in brain and pituitary tissue samples collected from anaesthetized and cisternally cannulated rats. Control rats were sham operated. In lesioned rats we observed: (a) 60% decrease in the immunoreactive beta-endorphin concentrations in the cerebrospinal fluid, (b) decreased immunoreactive ACTH and beta-endorphin levels in the hypothalamus, in the thalamus and in the amygdala, (c) unaffected immunoreactive ACTH/beta-endorphin levels in the septum and in the hippocampus, (d) decreased immunoreactive beta-endorphin levels both in the anterior and neurointermediate pituitary but unchanged immunoreactive ACTH contents in the anterior lobe, and (e) unaffected immunoreactive ACTH and beta-endorphin levels in the plasma under stressful conditions. From these findings the following conclusions can be drawn: (1) more than 50% of the beta-endorphin-like peptide content of the cerebrospinal fluid originates from the periventricular nuclei of the hypothalamus and thalamus in the rat; (2) the loss of the hypothalamic control probably enhances the intracellular proteolytic degradation of beta-endorphin both in the anterior and neurointermediate pituitary lobe; (3) rats with mediobasal hypothalamic lesion cannot react to the stressful stimuli of ether anaesthesia or cisternal cannulation with elevated plasma immunoreactive ACTH and beta-endorphin levels.

Inadequate treatment response to des-enkephalin-gamma-endorphin compared with thioridazine and placebo in schizophrenia

The possibility of an involvement of peptidergic systems in schizophrenia has been under investigation for a number of years. Studies of the efficacy of des-tyr-gamma-endorphin were equivocal; more recent studies with des-enkephalin-gamma-endorphin have reported some activity but the peptide has only been investigated as an adjunct to neuroleptic medication, apart from one very small active reference comparator study. In the multicentre study reported here, 96 patients suffering from schizophrenia (DSM-III with a current exacerbation if chronic) were allocated randomly to double-blind treatment with either des-enkephalin-gamma-endorphin (DE-gamma-E) (Org 5878) 10 mg given as a once daily intramuscular injection for 4 weeks, thioridazine 400 mg orally in 2 divided doses or placebo using a double-dummy technique to preserve blindness. There was a significant advantage for thioridazine compared with placebo registered on all measures at weeks 3 and 4. There was no difference between DE-gamma-E and placebo. There was a significant difference between thioridazine and DE-gamma-E at weeks 3 and 4 registered on the MSS and at week 3 registered on the BPRS. The lack of efficacy of DE-gamma-E suggests that the theories that the endorphins have an important role in schizophrenia have to be revised. The need for well designed placebo controlled studies for assessing efficacy in schizophrenia is emphasized.

Endorphin-like immunoreactivities in uncultured and cultured human peripheral blood mononuclear cells

It has been reported that cells of the immune system produce and release considerable amounts of pro-opiomelanocortin (POMC) -derived peptides in response to coculture with a variety of stimulatory agents. The present study investigated whether extracts of human peripheral blood mononuclear cells (PBMC) contain immunoreactivity for beta-endorphin (beta E) and related peptides. Using four endorphin RIA systems with different specificities, extracts of freshly isolated PBMC and PBMC cultured in the presence or absence of mitogens or of corticotropin releasing factor (CRF) and vasopressin (VP), were analyzed. With a radioimmunoassay (RIA) system directed to the midportion of beta E, immunoreactivity (MP beta E-IR) was readily detectable, although the concentration was extremely low (ca. 200 pg/10(7) cells). beta E immunoreactivity (beta E-IR) and alpha-endorphin immunoreactivity (alpha E-IR), as determined in C-terminally directed RIA systems, were present in even lower concentrations. gamma-Endorphin immunoreactivity (gamma E-IR) was hardly detectable. Of subsets enriched in T-cells, B-cells or monocytes, the highest concentration of MP beta E-IR was detected in extracts of monocytes. Coculture of PBMC with the mitogen Concanavalin A (Con A) or Phytohaemagglutinin (PHA) increased the amount of MP beta E-IR in extracts of the cells. No increase in alpha E-IR, however, was detected, whereas beta E-IR was only increased in extracts of cells cultured in the presence of Con A. No increase, in any of the immunoreactivities, was observed in extracts of PBMC cultured with bacterial lipopolysaccharide (LPS) or with the combination of CRF and VP, both stimuli that have been reported to induce POMC peptides in cultured PBMC. The present data show that human PBMC contain endorphin-like immunoreactivity, but in very small amounts. The extremely low concentrations and the ineffectiveness of LPS and the combination of CRF and VP to increase the endorphin-like immunoreactivity raise questions about the reported capacity of PBMC to synthesize POMC-derived peptides.

Isoproterenol-stimulated release of beta-endorphin and related peptides from the rat pituitary neurointermediate lobe in vitro: evidence for preferential release of certain molecular forms of beta-endorphin

The intermediate lobe of the pituitary gland synthesizes the multifactorial precursor molecule pro-opiomelanocortin (POMC), from which, through a process of post-translational enzymatic processing, beta-endorphin-(1-31) (beta E) and a variety of N alpha-acetylated and C-terminally shortened forms of this peptide are generated. Using an in vitro superfusion system, the release of these endorphins from intact rat neurointermediate lobes (NILs) was investigated under basal and isoproterenol (ISO) stimulated conditions. Superfusion of NILs with the beta-adrenergic agonist ISO (30 min pulse) resulted in a rapid, sustained and concentration-dependent stimulation of the release of beta E-like immunoreactivity (beta E-IR) over basal as determined with an antiserum directed against the C-terminus of the beta E- (1-31) sequence (10(-6) M: + 145%; 10(-7) M: + 73%; 10(-8) m: + 41%). The release of N(alpha)-acetylated-endorphin-like immunoreactivity (AcE-IR) was stimulated to a similar extent. These effects of ISO were antagonized by the competitive alpha-adrenoceptor antagonist propranolol in a concentration-dependent manner, indicating the involvement of alpha-adrenoceptors. The beta-related peptides released from the NILs under basal and ISO-stimulated conditions were further characterized, based on their retention times in a reversed-phase HPLC system and their reactivity with specific antisera recognizing respectively the midportion of beta E, the N-terminus of acetylated endorphins, the C-terminus of tau-endorphin (beta E-(1-17); tau E), or the C-terminus of alpha-endorphin (beta E-(1-16); alpha E). In HPLC fractionated superfusates 10 peaks were resolved that reacted with the midportion beta E antiserum. In superfusates collected under basal conditions, three major peaks possessed chromatographical and immunological characteristics of Ac beta E-(1-26), Ac beta E- (1-27) Ac beta E-(1-31). In addition, a prominent peak was found eluting around the retention time of beta E-(1-31), that contained both acetylated and non-acetylated material. Six smaller peaks were observed, with the characteristics of beta E-(1-26) and beta E-(1-27) (these peptides were not resolved with the HPLC system used), Ac tau E, tau E, Aa alpha E, and des-tyrosine-alpha E (DT alpha E), respectively. In superfusates collected during superfusion of NILs with ISO (10(-6) M) all peaks were increased. However, those eluting as beta E-(1-31), beta E-(1-26)/beta E-(1-27), Ac beta E-(1-26) and Ac tau E appeared to be preferentially stimulated.(ABSTRACT TRUNCATED AT 400 WORDS)

Effects of chronic treatment of rats with dopamine receptor drugs on the post-translational processing of Beta-endorphin in the neurointermediate lobe of the pituitary gland

Abstract To investigate whether chronic changes in the activity of proopiomelanocortin cells in the neurointermediate lobe (NIL) of the pituitary gland are associated with changes in the enzymatic processing of beta-endorphin (betaE), the effects of treatment of rats with the dopamine receptor antagonist haloperidol or the dopamine receptor agonist bromocriptine (2.5 mg.kg(-1) sc, once daily for 21 days) were studied on the content of betaE-related peptides in the NIL and on the release of these peptides from NILs in an in vitro superfusion system. Treatment with haloperidol increased, and with bromocriptine decreased the tissue content and the release of N(alpha)-acetyl-, beta-, gamma- and alpha-endorphin-immunoreactivity (AcE-, betaE-, gammaE, and alphaE-IR). The endorphin-IR was further characterized using reversed-phase high-performance liquid chromatography and specific radioimmunoassay systems, and the following peptides were identified: des-tyrosine alpha-endorphin (DTalphaE), alphaE, AcalphaE, gammaE, AcgammaE, betaE-(1-31), AcbetaE-(1-31), AcbetaE-(1-27), AcbetaE-(1-26) and betaE-(1-26)/betaE-(1-27) (the latter peptides were not separated with the high-performance liquid chromatography system used). Analysis of NIL superfusates indicated that all peptides found in the tissue were released in vitro. In addition, an as yet unidentified acetylated IR-endorphin component was found which was not observed in extracts of NIL tissue, and therefore was probably formed during release. Following haloperidol treatment, the levels of all betaE-related peptides detected were increased in the tissues as well as superfusates, the increase in AcbetaE-(1-27) being most and that in betaE-(1-26)/betaE-(1-27) least pronounced. Following bromocriptine treatment, the concentrations of all peptides in tissues and superfusates were decreased as compared to vehicle controls. The acetylated endorphins, in particular AcbetaE-(1-27), were most affected and betaE-(1-26)/betaE-(1-27) least affected. The results indicate that chronic modulation of the synthesizing and secretory activity of proopiomelanocortin cells in the NIL is parallelled by changes in the enzymatic processing of betaE.

Effects of chronic treatment with haloperidol and bromocriptine on the processing of beta-endorphin to gamma- and alpha-endorphin in discrete regions of the rat pituitary gland and brain

beta-Endorphin is the putative precursor molecule of gamma- and alpha-endorphin. To investigate whether long-term changes in the activity of cells producing beta-endorphin are paralleled by alterations in the enzymatic processing of beta-endorphin, the effects of chronic treatment of rats with dopamine (DA) receptor ligands were examined on the content of immunoreactivity of beta-, gamma- and alpha-endorphin of dissected regions of the pituitary gland and the brain. Treatment with the DA receptor antagonist, haloperidol, resulted in a significant increase in the concentration of immunoreactivity for beta-, gamma-, and alpha-endorphin in the neurointermediate lobe, and of beta-endorphin in the anterior lobe of the pituitary gland. Levels of immunoreactivity of alpha-melanotropin and beta-endorphin in plasma were elevated, but those of corticosterone were decreased. This indicates that, in the intermediate lobe, both the biosynthetic and the secretory activity of cells producing beta-endorphin had increased, whereas in the anterior lobe, the secretory activity of beta-endorphin cells had decreased. No effects were observed on the ratios beta-endorphin/gamma-endorphin and beta-endorphin/alpha-endorphin in the intermediate lobe. In the anterior lobe however, the ratio beta-endorphin/alpha-endorphin had significantly increased. The effects of chronic treatment with the DA receptor agonist, bromocriptine, on levels of hormones in pituitary and plasma were opposite to those induced by haloperidol. In the brain, treatment with haloperidol selectively increased the content of immunoreactivity for beta-, gamma- and alpha-endorphin of the hypothalamus and the hippocampus and did not affect levels of peptides in the other regions of the brain studied.(ABSTRACT TRUNCATED AT 250 WORDS)

Characterization of beta-endorphin-immunoreactivity in limbic brain structures of rats self-administering heroin or cocaine

The effects of intravenous self-administration of 30 micrograms infusions of either heroin or cocaine, or saline on the concentrations of beta-endorphin-immunoreactivity (beta E-IR) in the anterior part of the rat brain limbic system were studied. Self-administration of heroin and cocaine for 5 daily sessions resulted in a marked reduction of the concentrations of beta E-IR in the nucleus accumbens, rostral striatum, septum and hippocampus at the time of the scheduled next session on day 6. In pooled extracts of these regions from rats receiving saline, combined application of high-pressure liquid chromatography (HPLC) fractionation and specific radioimmunoassays revealed the presence of a number of beta E-related peptides co-chromatographing with synthetic non-acetylated and acetylated alpha, beta- and gamma-type endorphins. Similar profiles were found after HPLC fractionation of extracts of these regions from rats self-administering heroin and cocaine. Rats self-administering heroin or cocaine, however, showed decreased amounts of all detected forms of beta-endorphin as compared to saline rats. These findings indicate that both self-administration of an opiate that induces psychic as well as physical dependence and of a non-opiate stimulant inducing psychic but not physical dependence, results in a significant decrease of beta E and related peptides in limbic brain regions of the rat. All forms of beta E detected after HPLC were equally affected, suggesting an overall effect of the drugs on peptide turnover. These results suggest that beta E and related peptides may be involved in the neurochemical mechanisms underlying psychic dependence to drugs.

Criteria for evaluating improvement in schizophrenia in psychopharmacological research (with special reference to gamma endorphin fragments)

A review of treatment trials with DT gamma E revealed widely discrepant results. Relevant variables were the variety of measures employed for monitoring psychotic symptoms, and the different criteria used to judge the degree of improvement. The authors suggest a uniform outcome criterion for early trials of new treatments, which would generate more consistent and comparable results between studies, and give a stronger indication of the value of the treatment under test. When the data from the various treatment trials of DT gamma E were reanalysed, applying a uniform outcome criterion of improvement of a change of 80% or more on rating-scale score, the results were more consistent than would have been suspected from the original reports.

Increased concentration of alpha- and gamma-endorphin in post mortem hypothalamic tissue of schizophrenic patients

The concentrations of alpha-, beta- and gamma-endorphin were determined by radioimmunoassay in HPLC fractionated extracts of post mortem hypothalamic tissue obtained from schizophrenic patients and controls. The hypothalamic concentration of alpha- and gamma-endorphin was significantly higher in patients than in controls (+72.9% and +50.5% respectively). No difference was found in the concentration of beta-endorphin, the putative precursor of alpha- and gamma-endorphins. These results suggest a deviant metabolism of beta-endorphin in the brain of schizophrenic patients. Whether this phenomenon is related to the psychopathology, or is a consequence of ante mortem farmacotherapy, remains to be established.

Des-enkephalin-gamma-endorphin: bioavailability in rats following the subcutaneous and intramuscular route of administration

A pharmacokinetic study with [3H]des-enkephalin-gamma-endorphin (3H-DE gamma E) was performed in rats after the intravenous, subcutaneous and intramuscular route of administration. Disappearance of non-metabolized 3H-DE gamma E from blood upon intravenous dosing followed a biphasic decay with half-lives of 0.7 +/- 0.3 (+/- S.D.) min for the initial distribution phase and 6.3 +/- 2.7 min for the terminal elimination phase. The central and peripheral volumes of distribution were strikingly high (0.38 and 0.55 1 X kg-1, respectively). Extensive metabolism occurred already within the first minutes after injection. The blood clearance rate was found to be 0.29 +/- 0.12 1 X min-1 X kg-1, which value points to remarkable extrahepatic elimination of the neuropeptide. As compared to the intravenous route of administration, subcutaneous or intramuscular injection of 3H-DE gamma E resulted in low but longer-lasting peptide levels in blood. These levels reached already peak values at 2 min after both routes of administration and then declined to below the limit of detection at 2-3 h. The absolute bioavailability of DE gamma E after subcutaneous injection amounted to 30.9 +/- 16.3% (range 16.0-46.9%), whereas the bioavailability after intramuscular injection was observed to be 3.5 times lower (8.5 +/- 3.0%; range 4.6-12.0%). These data suggest that subcutaneous dosing of DE gamma E might be more effective in displaying CNS activity than the intramuscular route.

Paracrine interactions in the anterior pituitary

The topographical affinity between certain cell types in rat anterior pituitary as well as the presence of biogenic amines, neuropeptides, growth and tissue factors in specific cell types suggest participation of paracrine control mechanisms in the regulation of anterior pituitary hormone secretion. Due to the recent advances in the separation of pituitary cell types and the development of three-dimensional cell cultures, direct experimental evidence for control by intercellular messengers has become available. The stimulation of PRL release from superfused pituitary cell aggregates by LHRH has been shown to be mediated by gonadotrophs. Gonadotrophs appear to secrete a factor with PRL-releasing activity. Gonadotrophs also modulate the stimulation of PRL release by angiotensin II. Interaction of somatotrophs with an unknown small-sized cell type strongly amplifies the GH response to adrenaline, GRF and VIP. The latter phenomenon requires the permissive action of glucocorticoids. Some of these in vitro observations can be correlated with recently reported in vivo actions of LHRH, PRL and angiotensin II and with pathophysiological changes in the pituitary.

N alpha-Acetyl-gamma-endorphin is an endogenous non-opioid neuropeptide with biological activity

N alpha-acetyl-gamma-endorphin (Ac gamma E) was identified in the rat neurointermediate pituitary, based on its immunological properties, comigration with synthetic Ac gamma E on HPLC and resistance to aminopeptidase-M degradation. The peptide appeared to be the main form of gamma-endorphin (gamma E) in this tissue and in brain areas remote from the hypothalamus (hippocampus, septum, amygdala). The anterior pituitary, the hypothalamus and the thalamus contained almost exclusively the non-acetylated form of gamma E. In contrast to gamma E, Ac gamma E was completely devoid of specific affinity for brain opiate binding sites. Yet, the peptide mimicked gamma E in that it potently attenuated passive avoidance behaviour in rats, when injected topically into the nucleus accumbens. It is concluded that Ac gamma E is an endogenous neuropeptide with non-opioid biological activity. N alpha-acetylation may not merely represent a mechanism for the inactivation of opioid activities of endorphins, but rather allow the organism to select specific sets of biological activities that reside in the endorphin structure.

Pro-opiocortin peptides in rat cerebrospinal fluid

Cerebrospinal fluid (CSF) taken from rats implanted with chronic cisternal cannulae was subjected to gel filtration chromatography on Sephadex G-50. Fractions were monitored using radioimmunoassays for N-terminal pro-opiocortin (N-POC), gamma 3-melanotropin (gamma 3-MSH), C-terminal adrenocorticotropin (C-ACTH), alpha-endorphin, beta-endorphin, gamma-lipotropin (gamma-LPH) and alpha-MSH. Two peaks which corresponded in elution position to rat N-POC (1-74) and gamma 3-MSH were detected. The major C-ACTH-immunoreactive (IR) peak was found to correspond to 14k ACTH. While no alpha-endorphin immunoreactivity was detected in rat CSF, three beta-endorphin-IR peaks were identified in positions expected for beta-LPH, beta-endorphin (1-31) and beta-endorphin (1-27), as well as a major peak of activity with the elution characteristics and cross-reactivity of rat gamma-LPH. HPLC of the alpha-MSH-IR material in rat CSF revealed the presence of a major peak of immunoreactivity whose retention time did not correspond to the known oxidised and reduced forms of alpha-MSH and its desacetylated and diacetylated derivatives. The identity of this peak is unknown.

Des-Tyr1-gamma-endorphin (DT gamma E) and des-enkephalin-gamma-endorphin (DE gamma E): plasma profile and brain uptake after systemic administration in the rat

The plasma disappearance, metabolism and uptake in the brain of [3H-Phe4]-DT gamma E and [3H-Lys9]-DE gamma E were investigated following systemic administration of these neuroleptic-like peptides to rats. 3H-DT gamma E, 3H-DE gamma E and their radioactive metabolites in plasma and brain extracts were determined by reversed-phase HPLC. Plasma disappearance of DT gamma E upon intravenous (IV) dosing followed a biphasic pattern with half-lives of 0.7 min (distribution phase) and 5.5 min (elimination phase). For DE gamma E the plasma disappearance curve was best characterized by a one-compartment model since a second elimination phase was hardly detectable by our methods. The corresponding half-life was 0.6 min, probably representative for the initial distribution phase of DE gamma E. Both neuropeptides distributed rapidly over the larger part of the extracellular fluid. Following the IV route of administration, brain uptake of DT gamma E and DE gamma E appeared to be low. Brain levels of DT gamma E decreased from 0.0075% to 0.0031% of the administered dose/g tissue at 2-15.5 min after injection, whereas those of DE gamma E decreased very rapidly from 0.0174% of the dose/g brain tissue to below the detection limit at 2-4.5 min after injection. As compared to the IV route of administration, subcutaneous (SC) injection of DE gamma E resulted into lower but remarkably longer-lasting peptide concentrations in plasma as well as in brain, possibly because of a sustained release from the SC site of injection.(ABSTRACT TRUNCATED AT 250 WORDS)

gamma-Endorphin generating endopeptidase in rat brain: subcellular and regional distribution

beta-Endorphin is converted into the biologically active fragment gamma-endorphin by an endopeptidase which we term "gamma-endorphin generating endopeptidase". Subcellular and regional distributions of this endopeptidase activity in rat brain were studied by a newly developed assay. After subcellular fractionation of rat brain tissue gamma-endorphin generating endopeptidase activity was predominantly recovered in the cytosolic fraction. A 10 to 15 fold lower activity was present in synaptosomes, mitochondria and synaptic membranes. Hardly any endopeptidase activity was detected in nuclei and myelin. The endopeptidase activity in cytosolic and particulate fraction was found throughout brain, pituitary and spinal cord in a rather homogeneous fashion. Cytosolic activity in all brain parts was 10 to 15 fold higher than the activity in the particulate fraction. It is suggested that rather the beta-endorphin distribution than the endopeptidase is restricting for gamma-endorphin production in certain brain parts.

Dopamine inhibits the release of immunoreactive beta-endorphin from rat hypothalamus in vitro

Mediobasal hypothalamus tissue (MBH) from adult male rats was incubated in Krebs-Ringer bicarbonate medium (KRB). KRB was changed at 15 min intervals and the concentration of immunoreactive beta-endorphin (beta-ENDi) in the medium was measured by radioimmunoassay. Incubation of MBH tissue in normal KRB resulted in a constant release rate of beta-ENDi of approximately 1% of the tissue content per h. KRB containing 45 mM K+ causes a two fold increase in the release rate of beta-ENDi which was Ca2+ dependent. Dopamine (0.01-1.0 microM) inhibits both the spontaneous and the K+-stimulated release of beta-ENDi in a dose related manner. The dopamine receptor blocking agent haloperidol prevents this inhibitory effect of dopamine. The selective D-1 receptor agonist SKF 38393 does not affect the release rate of beta-ENDi; whereas the selective D-2 receptor agonist LY 141865 inhibits both the spontaneous and K+-stimulated release of beta-ENDi. The effects of LY 141865 can be blocked by (-)-sulpiride, a selective D-2 receptor antagonist. Norepinephrine only weakly inhibits the K+-stimulated release of beta-ENDi, an effect that can be blocked by haloperidol but not by the alpha-adrenoceptor blocker phentolamine. At concentrations tested (0.01-1.0 microM), isoproterenol, 5-hydroxytryptamine, carbachol and 8-Br-cAMP (1.0 microM) do not affect beta-ENDi release. It is concluded that dopamine can inhibit the release of beta-ENDi from hypothalamic neurons via a D-2 receptor mechanism.

Isolation and characterization of alpha-endorphin and gamma-endorphin from single human pituitary glands

alpha-Endorphin and gamma-endorphin, two closely related peptides of the pro-opiomelanocortin family with characteristic biological activities, were purified to homogeneity from single human pituitary glands and chemically identified. Isolation of the peptides was based on size fractionation by Sephadex G-75 chromatography followed by two HPLC steps using reverse-phase and paired-ion reverse-phase systems and was monitored by radioimmunoassay. During the isolation procedure alpha- and gamma-endorphin-sized material behaved chromatographically and immunologically indistinguishably from synthetic alpha- and gamma-endorphin. The amino acid composition and NH2-terminus of isolated peptides demonstrated their identity as authentic alpha-endorphin and gamma-endorphin. Acetylated forms were absent. In addition, evidence is provided that large forms with alpha- and gamma-endorphin immunoreactivity detected during gel filtration are human lipotropin-(1-74) and -(1-75), respectively. The data substantiate that alpha-endorphin and gamma-endorphin exist as endogenous peptides in the human pituitary gland.

Local biotransformation of des-Tyr1-gamma-endorphin in brain studied by a push-pull technique and HPLC analysis

The biotransformation of [3H]des-Tyr1-gamma-endorphin locally in rat brain was studied by perfusion of the peptide via a push-pull cannula implanted in the nucleus caudatus. Metabolites were analyzed by high-pressure liquid chromatography. Free [3H]phenylalanine and a [3H]peptide with chromatographic properties of beta-endorphin2-13 were formed during push-pull perfusion. The method presented enables the detection of local proteolytic events in the brain and provides a novel tool for studies on neuropeptide biotransformation.

Localization and identification of gamma-endorphin and beta-endorphin-like peptides in the hypothalamus and ventral forebrain of the rat

Gamma-endorphin (gamma E) and related peptides were localized in the brain of the rat, and compared to the distribution of beta-endorphin related peptides. gamma E-like immunoreactivity (gamma E-LI) was shown to exist only in brain regions known to receive innervation from POMC neurons but not in their pericaria in the arcuate nucleus. Nuclei of the hypothalamus and ventral forebrain contained the major concentration of gamma E-LI and extracts from these regions were purified and subjected to HPLC in order to identify gamma E-related peptides. gamma E, des-tyrosine1 gamma E, des-enkephalin-gamma E, and alpha-N acetyl gamma E co-elutable peptides as well as various unidentified forms were evident. This study provides evidence of the endogenous presence of pharmacologically active gamma E-related peptides in brain regions where they have been postulated to modulate dopaminergic transmission.

The effect of microwave irradiation on vasopressin in plasma and hypothalamo-neurohypophyseal system

Radioimmunoreactive vasopressin was measured in plasma, neurohypophysis and hypothalamus of the rats after different procedures of killing: a) microwave irradiation; b) decapitation; c) decapitation following a stress induced by immobilization in a restrainer. Vasopressin content in the neurohypophysis and hypothalamus was much lower in microwave irradiated than in both decapitated and stressed decapitated rats. In addition, the data from microwave technique were inconsistent with a large scatter. Plasma vasopressin concentration was elevated in both the microwave irradiated and stressed decapitated rats, demonstrating that restraining of the animals induced an excessive stress. Microwave irradiation technique including the necessary manipulation of the animal proved to be less suitable than decapitation technique for the measurement of vasopressin. It is likely that vasopressin in the hypothalamus and neurohypophysis is relatively resistant against post-mortem proteolysis.

Characterization of N alpha-acetyl-alpha-endorphin from rat neurointermediate lobe and its distribution in pituitary and brain

N alpha-Acetyl-alpha-endorphin was characterized from rat neurointermediate lobe. The distribution of the acetylated and the non-acetylated form of alpha-endorphin in dissected areas of pituitary and brain appeared to be uneven. alpha-Endorphin appeared to be the main peptide in the anterior pituitary, whereas in the neurointermediate lobe N alpha-acetyl-alpha-endorphin accounted for most of the alpha-endorphin immunoreactivity. In the brain, the highest concentration of alpha-endorphin immunoreactivity was found in the hypothalamus. In hypothalamus and thalamus alpha-endorphin predominated, whereas in amygdala, hippocampus and septum N alpha-acetyl-alpha-endorphin represented most of the alpha-endorphin-immunoreactivity. In view of the non-opioid properties of acetylated endorphins, it is suggested that acetylation represents a mechanism allowing the organism to specifically select the non-opioid behavioral activities enclosed in the endorphin sequence.

Effects of beta-endorphin and its fragments on inhibitory avoidance behavior in rats

The effects on retrieval of a one-trial learning inhibitory avoidance response of beta-endorphin, alpha-endorphin, and gamma-endorphin, given prior to test have been studied in rats. beta-Endorphin (beta-LPH 61-91) in a relatively low dose (1.56 micrograms sc. or 50 ng icv.) facilitated inhibitory avoidance behavior, while a higher dose (10 micrograms sc. or 100 ng icv.) caused bimodal changes (facilitation in 50% of the animals and attenuation in another 40%. Peripheral injection of gamma-endorphin attenuated inhibitory avoidance behaviour in a dose-dependent manner. The C-terminus of beta-endorphin (beta-LPH 78-91) was ineffective. alpha-Endorphin facilitated inhibitory avoidance behavior in a dose dependent manner. Naltrexone pretreatment antagonized the bimodal effect of beta-endorphin: following pretreatment with the opiate antagonist the low latency component disappeared, but the facilitatory effect of the neuropeptide remained the same. It is suggested that beta-endorphin carries more than one bit of behavioral information. Inherent activities either related or unrelated to naltrexone-sensitive opiate as well as biotransformation into alpha- and gamma-endorphin may contribute to the multiple behavioral effects of this neuropeptide.

Immunoreactive beta-endorphin in the hypothalamus of female rats: changes in content and release during prepubertal development

Female Wistar rats of different ages (1-45 days) were used. Extracts were made of the mediobasal hypothalamus (MBH) and beta-endorphin immunoreactivity (beta-ENDi) was quantitated by radioimmunoassay. Low but significant amounts of beta-ENDi (6.5 ng/MBH) were present on the first postnatal day. Hypothalamic beta-ENDi content did not change during the first week but decreased during the second week to a minimum (4.5 ng/MBH) on day 14. Thereafter, beta-ENDi increased rapidly to 13 ng/MBH on day 28 and remained at this level. Gel filtration showed that beta-ENDi substances with chromatographic characteristics identical to those of beta-END and beta-LPH were present in MBHs of 14-, 20- and 45-day-old rats. A beta-ENDi substance, possibly representing beta-END1-27, was nearly absent on day 14, but represented a major component of the MBH of the 45-day-old rat. In vitro incubation of MBH resulted in spontaneous release of beta-ENDi. Depolarization of neuronal membranes by incubation in medium containing 45 mMK+ stimulated beta-ENDi release. Both the spontaneous and K+-stimulated release of beta-ENDi were low on day 10 but reached postpubertal levels on day 20. These observations lead us to propose that the beta-ENDi-containing neurons in the hypothalamus of developing female rats rapidly mature between 14 and 20 days after birth. This may be causally related to the rapid decrease in circulating FSH levels that occurs during this period.

beta-Endorphin proteolysis by guinea-pig ileum myenteric plexus membranes: increased gamma-endorphin turnover after chronic exposure to morphine

The influence of chronic morphine exposure in vitro on the biotransformation of beta-endorphin (beta E) was investigated using the myenteric plexus-longitudinal muscle of guinea-pig ileum. A membrane preparation was incubated with beta E and the degradation of beta E as well as the accumulation of several beta E fragments in the incubation medium were followed with time. The levels of peptides were determined by specific radioimmunoassays after separation by high-pressure liquid chromatography. It was found that exposure to morphine did not affect the disappearance of beta E, but altered the time course of accumulation of beta E fragments. In fact, the accumulation of gamma-endorphin, alpha-endorphin and des-tyrosine1-alpha-endorphin was enhanced, while that of des-tyrosine1-gamma-endorphin was not change. Additionally, the disappearance of gamma-endorphin appeared to be stimulated by morphine exposure. These data provide evidence that the fragmentation of beta E is changed by chronic morphine exposure in such a way that the turnover of gamma-endorphin is increased.

Neuropeptides and cerebrospinal fluid

Neuropeptides are present in brain tissue as well as in cerebrospinal fluid. Studies from a variety of disciplines have demonstrated that neuropeptides have neuromodulatory activities. Such activities are apparent in the involvement of neuropeptides in the regulation of adaptive, autonomic, and endocrine functions of the brain. Neuropeptides exert their neuromodulating influences by acting as neurotransmitters or as neurohormones. The neurotransmitter function of neuropeptides is associated with their synthesis in situ in brain and anatomical distribution via neuropeptidergic fibre systems. The presence of such neuropeptides in cerebrospinal fluid may be due primarily to drainage into the cerebrospinal fluid compartments, their levels being a reflection of cellular processes such as biosynthesis, release, and metabolism. On the other hand, neuropeptides functioning as neurohormones may be actively delivered into the cerebrospinal fluid from central or peripheral sources. They employ the pathways of cerebrospinal fluid circulation as avenues of transport, and their cerebrospinal fluid levels may be functionally related to neurohormonal activity. In either case the cerebrospinal fluid levels are informative on the neuropeptide climate in brain; thus their determination is meaningful. The methodology for the sensitive and specific determination of neuropeptides is becoming available. Determination of neuropeptides may well be of diagnostic value in clinical practice.

Gamma-endorphin-like peptides in pituitary tissue: evidence for their existence in vivo

Beta and gamma endorphin-like peptides were measured by radioimmunoassay in whole pituitary. Boiling of acetic acid extracts prior to tissue disruption increased the concentration of both beta E- and gamma E-like peptides. The gamma E-like immunoreactivity from the neurointermediate lobe of the pituitary co-eluted with synthetic gamma E upon gel permeation chromatography. Immunoreactivity for beta E-like and gamma E-like peptides in the intermediate lobe of the pituitary was also shown by immunoperoxidase staining. The results suggest that gamma E-like peptides are present primarily in the pars intermedia in vivo and do not arise as artifacts of acid extraction of pituitary tissue.

Proteolysis of beta-endorphin in brain tissue

The processing of beta-endorphin by brain enzymes into peptides related to the behaviorally active gamma- and alpha-type endorphins and the sequence of proteolytic events in the conversion process are described. Multiple enzyme activities contribute to the generation of the peptides with neurotropic activity. It is proposed that the processing into gamma- and alpha-type neuropeptides is a post-secretional event. The enzymes involved may have a key role in the nature and levels of neurotropic beta-endorphin fragments in the brain.

Regional distribution of alpha- and gamma-type endorphins in rat brain

The regional distribution of Met-enkephalin, beta-endorphin and alpha- and gamma-type endorphins in rat brain was investigated. To that end, brains were dissected into anatomically defined areas. Acetic acid tissue extracts were fractionated using an HPLC system suitable for separation of endorphins and peptide concentrations were subsequently measured by specific radioimmunoassay systems. The distribution of Met-enkephalin and beta-endorphin through the brain was fairly uneven and in accordance with results obtained by others. The peptides alpha-endorphin, gamma-endorphin, des-Tyr-alpha-endorphin (DT alpha E) and des-Tyr-gamma-endorphin (DT gamma E) were detectable in almost all brain areas. Their distribution, however, appeared to be uneven. Hypothalamus and septum showed the highest levels of alpha- and gamma-type endorphins. These regions also contained high amounts of beta-endorphin, underscoring a precursor function of this peptide in the formation of alpha- and gamma-type fragments. In general, levels of alpha-endorphin were higher than those of des-Try-alpha-endorphin, whereas the opposite was found for gamma- and des-Tyr-gamma-endorphin.

Contribution of the amino terminal tyrosine to the interaction of gamma-endorphin with opiate receptors

The putative behavioral hexadecapeptide, des-Tyr1-gamma-endorphin, has been compared with gamma-endorphin in an in vitro radioreceptor assay utilizing [3H] beta-endorphin as the labeled ligand and rat brain membranes as a source of opiate receptors. Under the conditions used, beta-endorphin and gamma-endorphin exhibit Kd's of 0.4 nM and 58 nM, respectively. The Kd of des-Tyr1-gamma-endorphin was estimated to be 42 micro M indicating that the amino terminal tyrosine in gamma-endorphin contributes about -4 kcal/mol at 30 degrees C to free energy of binding associated with the peptide-opiate receptor interaction. Circular dichroic spectra were obtained, and the only structural element discernible was a possible beta-turn. Thus, at physiological levels it seems unlikely that the des-Tyr1 fragment of gamma-endorphin will exhibit any significant interaction with the opiate receptor.

Influence of beta-lipotropin fragments on responsiveness of rats to electric footshock

Subcutaneous administration of graded doses of neuropeptides related to lipotropin (beta LPH) changed responsiveness of rats to electric footshock. gamma-Endorphin and related peptides increased the susceptibility of rats, whereas beta-endorphin induced a reversed effect. The enhanced responsiveness induced by DT gamma E, persisted for more than 24 hr and appeared to be of a central origin. Structure-activity relationship studies revealed that the sequence LPH 65-69 may contain the active core in this respect. An increased sensitivity to electric shock within one test procedure was observed with DT gamma E and alpha-endorphin. Prior experience with the test procedure diminished or abolished this effect of alpha-endorphin. It is suggested that beta-endorphin and its fragments play a physiological role in adaptive behavioral changes induced by peripheral stimuli.

Retention of passive avoidance behavior in rats following alpha- and gamma-endorphin administration: effects of post-learning treatments

Neuropeptides related to beta-endorphin (beta-LPH61-91) profoundly affect avoidance behavior. That gamma- and alpha-endorphin (beta-LPH61-77 and beta-LPH61-76, respectively) influence memory processes, has been investigated on rats. Using a one-trial learning, step-through passive avoidance paradigm, it was found that gamma-endorphin attenuates later retention of passive avoidance behavior when administered immediately or 3 h after learning; alpha-endorphin facilitates this response when given immediately after learning. Neither gamma- nor alpha-endorphin influence retention when the treatment is postponed for 6 h after learning. These data are interpreted as suggesting an opposite effect of gamma- and alpha-endorphin on consolidation processes.

Regional distribution of gamma- and beta-endorphin-like peptides in the pituitary and brain of the rat

Sensitive and specific radioimmunoassays for gamma- and beta-endorphin-like peptides (gamma E and beta E) were used to examine the distribution and relationship of these peptides in the pituitary and in microdissected nuclear brain areas of the male rat. In the pituitary, the highest amounts of gamma E and beta E were found in the neurointermediate region of the gland. On a molar basis, gamma E-like immunoreactivity was found to exist as a relatively constant proportion of beta E-like peptides throughout the pituitary. In the brain, while beta E-like peptides were detected in many brain areas, gamma E-like peptides were detected in only a limited number of sites. In most of these areas, the molar ratio of gamma E to beta E-like peptides closely approximated that found in the pituitary. However, in the ventromedial nucleus of the hypothalamus and nucleus accumbens a higher proportion of gamma E to beta E was measured. These results suggest preferential formation of gamma E or related peptides in certain areas of the brain may occur.